Type
Sandwich ELISA, HRP-labelled antibody
Applications
Stool
Storage/Expiration
Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Limit of Detection
0.3 ng/ml
Intra-assay (Within-Run)
n = 10; CV = 5.3 %
Inter-assay (Run-to-Run)
n = 10; CV = 6.4 %
Spiking Recovery
92.21%
Dilution Linearity
98.06%
Features
- European Union: for in vitro diagnostic use
- rest of the world: for research use only!
- The kit is intended for the quantitative determination of Lysozyme in stool.
- Assay format is 96 wells
- Components of the kit are provided ready to use or concentrated
Research topic
Diabetology - Other Relevant Products, Immune Response, Infection and Inflammation
Summary
Lysozyme is a relatively small enzyme consisting of a polypeptide chain of 129 amino acids and has a molecular weight of 14.6 kDa. Lysozyme is a glycosidase which, as a component of the innate immune system, is primarily directed against the murein-containing cell wall of gram-positive bacteria. Hence it is also called muramidase because it can cleave the murein (peptidoglycan) from bacterial walls by hydrosylating the beta-1,4-glycosidic bond between N acetylglucosamine and N-acetylmuramic acid.
Lysozyme is found in many secretions of the human body, including tears, saliva, blood serum and cerebrospinal fluid. It is produced in the tissues of the respiratory tract, kidneys and intestinal mucosa, as well as by neutrophils and macrophages. Under physiological conditions, about 80% of the lysozyme in the blood plasma is due to the breakdown of neutrophilic granulocytes. Normally, lysozyme is not detectable in the intestinal contents, or only in small amounts. However, fecal lysozyme can occur due to intestinal granulocytes. Lysozyme can be detected in all cells of the inflammatory infiltrate in Crohn's disease. Furthermore, lysozyme can be actively secreted into the intestinal lumen by monocytes and macrophages. Taking non-steroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, diclofenac) or COX-2 inhibitors (e.g. celecoxib) can cause irritation and damage to the lining of the gastrointestinal tract, ranging from small superficial lesions (erosions) to deeper ulcers (ulcers) to lighter and heavy bleeding. Therefore, if possible, the relevant medication should not be taken for a period of 14 days prior to carrying out the determination, in order not to influence the measurement of the degree of intestinal inflammation.
Applications:
- Inflammatory processes in the intestine
- Detection of a disturbed immunological barrier at the intestinal mucosa
Instructions for Use (RUO)
Instructions for Use (RUO)
Safety Information (RUO)
MSDS (RUO)
Other Documents
Declaration of Conformity
Find documents for the lot